Navigation Links
YM BioSciences Announces Data from Nimotuzumab Phase II Gastric Cancer Trial Reported at ASCO GI Symposium
Date:1/20/2011

MISSISSAUGA, ON, Jan. 20 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a life sciences product development company advancing a diverse portfolio of promising hematology and cancer-related products at various stages of development, today announced that results were reported from a randomized Phase II gastric cancer study of nimotuzumab being conducted by its licensees, Daiichi Sankyo Co., Ltd. in Japan and Kuhnil Pharma Co. Ltd., in Korea.

"The overall findings of the study are positive, and support the promise of nimotuzumab in this important global cancer market. Although not powered for statistical significance, in subgroup analyses these data demonstrated that EGFR-positive patients treated with nimotuzumab showed a potential improvement of Progression Free Survival and Overall Survival in gastric cancer. This is consistent with evidence that nimotuzumab selectively targets tissues over-expressing EGFR," said Dr. Nick Glover, President and CEO of YM BioSciences. "The authors of the study conclude that the selection of gastric cancer patients by EGFR status might be effective for future studies of nimotuzumab, and indicate that a Phase III clinical trial should be performed to examine these findings."

The results were reported in a poster being presented on January 20, 2011 at the ASCO Gastrointestinal Cancers Symposium in San Francisco, entitled: "Randomized phase II study of nimotuzumab, an anti-EGFR antibody, plus irinotecan in patients with 5-fluorouracil-based regimen-refractory advanced or recurrent gastric cancer in Korea and Japan: Preliminary results".

Trial Design and Results:

The study is a Phase II multi-center, randomized, open-label trial evaluating nimotuzumab ("N") (400 mg, IV weekly) plus irinotecan ("I") (150 mg/m2 IV every two weeks) compared to irinotecan alone in patients with advanced or recurrent gastric cancer who are refractory to a 5-fluorouracil-based regimen. The efficacy analysis was condu
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
3. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
4. Milestone Biosciences, LLC Further Strengthens Executive Management Team
5. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
6. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
7. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
8. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
9. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
10. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
11. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... COLLEGE STATION, Texas , July 28, 2014   The ... be a 177-key, 4-star boutique hotel in the heart of The ... Texas.  Photo - http://photos.prnewswire.com/prnh/20140725/130455 ... hotel within ATLAS , The ... standard rooms and suites, a sleek restaurant and bar, a wellness ...
(Date:7/26/2014)... NY (PRWEB) July 26, 2014 ... provides key market data on the Canada Endoscopy ... millions of US dollars, volume (in units) and ... - High-End Endoscopy Visualization Systems, Mid-Range Endoscopy Visualization ... Full Report at http://www.marketresearchreports.biz/analysis/213254 . , The ...
(Date:7/25/2014)... each person,s digestive tract. Scientists believe that some of ... infections, but their role in human health is not ... role of these bacteria, a team of researchers led ... in the bacterial populations of two research subjects over ... 25 issue of the journal Genome Biology , ...
(Date:7/25/2014)... New York (PRWEB) July 25, 2014 ... Market Research, "Biological Drugs Market - Global Industry Analysis, ... the global biological drugs market is estimated at USD ... at a CAGR of 10.1% from 2014 to 2020, ... in 2020. , The biological drugs market is witnessing ...
Breaking Biology Technology:Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 3Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3
... Idenix,Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical ... the treatment of human viral,and other infectious diseases, announced ... the 43rd Annual Meeting of the European,Association for the ... Milan, Italy,April 23 - 27, 2008. Full abstracts can ...
... Guaranteed Purchase Minimums - Carrington Provides Product Development, Manufacturing ... ... Distribution, IRVING, Texas, Feb. 25 Carrington,Laboratories, Inc. ... agreement with Universal Harvest Corporation of Nevada. Under the,terms of ...
... N.J., Feb. 25 Barr Pharmaceuticals,Inc. (NYSE: ... subsidiary, Duramed,Pharmaceuticals, Inc., has received notification that ... accepted for review its New Drug Application,(NDA) ... mg and ethinyl estradiol tablets 0.01 mg) ...
Cached Biology Technology:Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) 2Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) 3Carrington and Universal Harvest Sign Supply Agreement 2Duramed's Lo SEASONIQUE(R) NDA Accepted for Filing by FDA 2Duramed's Lo SEASONIQUE(R) NDA Accepted for Filing by FDA 3Duramed's Lo SEASONIQUE(R) NDA Accepted for Filing by FDA 4
(Date:7/27/2014)... might have survived the asteroid strike that wiped them ... later in history, scientists say. , A fresh study ... helped palaeontologists to build a new narrative of the ... They found that in the few million years before ... was experiencing environmental upheaval. This included extensive volcanic activity, ...
(Date:7/27/2014)... have shown the potential for global climate change to ... most part, ignored the interactions between increasing temperature and ... to damage crops. , A new study involving researchers ... significant, suggesting that policymakers need to take both warming ... , The study looked in detail at global production ...
(Date:7/25/2014)... first broad-scale estimate of air pollution removal by trees ... trees are saving more than 850 human lives a ... , While trees, pollution removal equated to an average ... impacts of that improvement are substantial. Researchers valued the ... nearly $7 billion every year in a study published ...
Breaking Biology News(10 mins):Dinosaurs fell victim to perfect storm of events, study shows 2Study: Climate change and air pollution will combine to curb food supplies 2Study: Climate change and air pollution will combine to curb food supplies 3First national study finds trees saving lives, reducing respiratory problems 2
... Colorado at Boulder has been awarded $1 million from ... of Energy to develop rapid solar- thermal chemical reactor ... and algae to synthesis gas. The three-year award ... Weimer of CU-Boulder,s chemical and biological engineering department. ...
... , Iron is vital to human life; for example, ... our blood red and supplies our cells with oxygen. However, ... iron deposits in the brain contribute to certain forms of ... malfunction of the blood transporter transferrin may be to blame. ...
... student in the division of marine geology and geophysics ... Marine and Atmospheric Science, was recently awarded the prestigious ... Geophysical Union (AGU) Fall 2007 Meeting. The prize ... and Future Directives of the Nicoya Peninsula Continuous GPS ...
Cached Biology News:University of Colorado at Boulder awarded $1 million for biofuels research 2Rusty worms in the brain 2Slow slip and slide dynamics 2
DNA fragmentation factor & Inhibitor of CAD...
Anti-MT3-MMP Membrane-Type Metalloproteinase-3; propeptide domain; rabbit host...
Anti-CoralHue Dronpa Green Monoclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
Chlamydia pneumoniae (TWAR)...
Biology Products: